MyMD

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

MyMD will continue to be the best health care provider by providing quality services and care, giving back to the community, and providing safe and healthy environment.

To ensure that everyone in our community has access to quality health care and medical services

MyMD has been recognized for its excellence in healthcare service, receiving awards for health care innovation, customer service, and community service.